Explore the vast range of titles available.

The ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) and ATP-binding cassette subfamily C member 6 (ABCC6) proteins play a prominent role in inhibiting ectopic calcification and arterial stenosis. Patients with ENPP1 Deficiency or infant onset ABCC6 Deficiency often present with pathological calcification, narrowed blood vessels, multiorgan dysfunction and high infant mortality. The heterogenous presentation and progression is well documented. Our objective was to characterize how these morbidities lead to burden of illness and poor quality of life across ages from the patient/caregiver perspective. Patients/caregivers were interviewed via phone using Institutional Review Board–approved questionnaires. Patient-reported outcomes were collected via validated instruments. Thirty-one caregivers and 7 patients participated: infant onset ABCC6 Deficiency, n = 6 (infants/children); ENPP1 Deficiency, n = 32 (13 infants, 12 children, 7 adults). ENPP1 and ABCC6-deficient children aged <8 years and aged 8–18 years reported poor school functioning (0.69 vs 0.72 effect size, respectively) and poor physical health (0.88 vs 1, respectively). In the total ENPP1 cohort, 72% (23/32) reported bone/joint pain and/or mobility/fatigue issues. Three of seven ENPP1-deficient adults reported moderate to severe pain (>4), as measured by the Brief Pain Inventory (BPI), that interfered with daily activities despite pain medication. Top reported burdens for caregivers of infants with ABCC6/ENPP1 Deficiencies included heart-related issues and hospitalizations. Treatment/medications, and hearing loss were the highest burdens reported by caregivers/families of the pediatric ENPP1 Deficiency cohort, whereas adults reported bone/joint pain and mobility impairment as the greatest burdens. Individuals with ENPP1 Deficiency or infant onset ABCC6 Deficiency experience lifelong morbidity causing substantial physical and emotional burden to patients/caregivers.

The ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) and ATP-binding cassette subfamily C member 6 (ABCC6) proteins play a prominent role in inhibiting ectopic calcification and arterial stenosis. Patients with ENPP1 Deficiency or infant onset ABCC6 Deficiency often present with pathological calcification, narrowed blood vessels, multiorgan dysfunction and high infant mortality. The heterogenous presentation and progression is well documented. Our objective was to characterize how these morbidities lead to burden of illness and poor quality of life across ages from the patient/caregiver perspective. Patients/caregivers were interviewed via phone using Institutional Review Board-approved questionnaires. Patient-reported outcomes were collected via validated instruments. Thirty-one caregivers and 7 patients participated: infant onset ABCC6 Deficiency, n = 6 (infants/children); ENPP1 Deficiency, n = 32 (13 infants, 12 children, 7 adults). ENPP1 and ABCC6-deficient children aged <8 years and aged 8-18 years reported poor school functioning (0.69 vs 0.72 effect size, respectively) and poor physical health (0.88 vs 1, respectively). In the total ENPP1 cohort, 72% (23/32) reported bone/joint pain and/or mobility/fatigue issues. Three of seven ENPP1-deficient adults reported moderate to severe pain (>4), as measured by the Brief Pain Inventory (BPI), that interfered with daily activities despite pain medication. Top reported burdens for caregivers of infants with ABCC6/ENPP1 Deficiencies included heart-related issues and hospitalizations. Treatment/medications, and hearing loss were the highest burdens reported by caregivers/families of the pediatric ENPP1 Deficiency cohort, whereas adults reported bone/joint pain and mobility impairment as the greatest burdens. Individuals with ENPP1 Deficiency or infant onset ABCC6 Deficiency experience lifelong morbidity causing substantial physical and emotional burden to patients/caregivers.

[...]the cardiologist informs them that some of the tests sug-gested abnormalities in their baby's arteries, and encourages the parents to consent to a genetic test that could provide additional clarity They agree to move forward with the test and the results show that their daughter was born with generalized arterial cal-cification of infancy (GACI), the infantile form of ENPP1 Deficiency, a rare disease characterized by abnormal mineraliza-tion and pathologie calcification of the arteries. What's more, the EveryLife Foundation study revealed that newborn screening and early diagnosis can yield significant economie benefits, as well as, improved long-term health outcomes. (https://everylife-foundation.org/wp-content/uploads/2023/09/EveryLife-Cost-of-Delayed-Diagnosis-in-Rare-Disease_Final-Full-Study-Report_0914223.pdf) According to the National Institutes of Health (NIH), there are approximately 7,000 rare diseases affecting between 25 and 30 million Americans each year (https://www.nih.gov/about-nih/what-we-do/nih-turn-ing-discovery-into-health/promise-precision-medicine/rare-diseases). According to Genomics England, the study will play a pivotal role in advancing early diagnosis and intervention, potentially leading to the creation of more comprehensive newborn screening programs that save lives by giving families timely clarity on their babies' conditions and informing next steps for appro-priate care Initiatives like these exemplify why I am more optimistic than ever about the future of newborn screening.

[...]if your family has a child living with a rare genetic disease, and if that disease happens to be on your state's screening panel, that is excellent news for you. HARNESSING THE POWER OF PARENTS AND ADVOCACY GROUPS I feel fortunate to work for a company that is developing therapies for rare mineralization disorders, and that works closely with patient communities and advocacy groups to raise awareness of these diseases. GACI Global, a parent-led advocacy group, is just one example of the power of parents to raise awareness of a rare disease, shorten time to diagnosis, and hopefully find a treatment in the future.

Ferropericlase (Mg,Fe)O is the second most abundant mineral in Earth’s lower mantle and a common inclusion found in subcratonic diamonds. Pyrolitic mantle has Mg# (100 × Mg/(Mg+Fe)) ~89. However, ferropericlase inclusions in diamonds show a broad range of Mg# between 12 and 93. Here we use Synchrotron Mössbauer Source (SMS) spectroscopy and single-crystal X-ray diffraction to determine the iron oxidation state and structure of two magnesiowüstite and three ferropericlase inclusions in diamonds from São Luiz, Brazil. Inclusion Mg#s vary between 16.1 and 84.5. Ferropericlase inclusions contain no ferric iron within the detection limit of SMS, while both magnesiowüstite inclusions show the presence of monocrystalline magnesioferrite ((Mg,Fe)Fe 3+ 2 O 4 ) with an estimated 47–53 wt% Fe 2 O 3 . We argue that the wide range of Fe concentrations observed in (Mg,Fe)O inclusions in diamonds and the appearance of magnesioferrite result from oxidation of ferropericlase triggered by the introduction of subducted material into sublithospheric mantle. This article reports finding of a highly oxidised mineral in diamond inclusion derived from mantle transition zone or lower mantle, very reduced areas on our planet. Such oxidised material is likely linked to subduction of carbonates into this region.

The transfer of T-DNA from Agrobacterium to plant cells is mediated by a system which involves the virB operon of the Ti plasmid. We report that VirE2 and VirD2, two T-DNA-associated proteins, as well as VirF, a protein known to be secreted into plant cells, are present in the periplasm and supernatant fractions of growing cells of Agrobacterium as are VirJ and ChvE, two known periplasmic proteins. Two cytoplasmic proteins, Ros and chloramphenicol acetyl transferase, and a VirE2 :: green fluorescent protein construct were not detected in the above fraction. Export of VirE2 into the culture supernatant did not require any Ti plasmid genes, except for VirE1, a specific chaperone for VirE2. The levels of the VirE2 and VirD2 proteins in the supernatant increased significantly when cells were grown at 19 degrees C as compared with 28 degrees C. When Agrobacterium expressed the oncogenic suppressive activity protein (Osa), VirE2 and VirF proteins could not be detected in the supernatant or the periplasm and the level of VirD2 was greatly reduced. However, oncogenic suppressive activity protein did not block the accumulation of VirJ and ChvE in the periplasm. Our data suggest that VirD2, VirE2, and VirF are transported across the cytoplasmic membrane by a specific pathway, independent of virB. Thus, transfer of the T-complex of Agrobacterium may take place in two steps, the first mediated by an unidentified pathway and the second by the virB system.